While there are some indications of aberrant MAPK/ERK activation in renal cell carcinoma [188], due to the focus of this review, we restrict our discussion to MAPK/ERK pathway in pediatric kidney cancer. The gene discussed is MAPK1; the disease is hereditary clear cell renal cell carcinoma.